Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 2, 2007, Pages 135-142

  Knudsen, S T ^a   Jeppesen, P ^a   Poulsen, P L ^a   Andersen, N H ^a   Bek, T ^a   Schmitz, O ^a   Mogensen, C E ^a   Rasmussen, L M ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Atherosclerosis; Blood glucose; Diabetes; Insulin; Metabolic control; OPG; Vascular calcifications

Indexed keywords

GLUCOSE; INSULIN; OSTEOPROTEGERIN;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL SIGNIFICANCE;

ADULT; BLOOD GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; MALE; OSTEOPROTEGERIN; RANDOM ALLOCATION; SINGLE-BLIND METHOD; SOMATOSTATIN;

EID: 33947135337     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510600987728     Document Type: Article

References (17)

1. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000;192:463-74.
2. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003.
3. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-7.
4. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4.
5. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003;88:1024-8.
6. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004;44:1970-6.
7. Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005;28:2176-80.
8. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006;47:1850-7.
9. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003;149:39-42.
10. Rasmussen L, Tarnow L, Hansen T, Parving H, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006;154:75-81.
11. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005;48:561-8.
12. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993;39:578-82.
13. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
14. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
15. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000;275:20959-62.
16. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002;521:180-4.
17. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.